መነሻ › ኖን-ስማል ሴል የሳንባ ካንሰር › ኢሊኖይ › Arlington Heights
በArlington Heights፣ IL ለኖን-ስማል ሴል የሳንባ ካንሰር የሚደረጉ ክሊኒካዊ ጥናቶች
ለኖን-ስማል ሴል የሳንባ ካንሰር የሚደረጉ 12 ጥናቶች በArlington Heights እና በአካባቢው ባሉ ቦታዎች (በወደ 30 ማይል ውስጥ) ተሳታፊዎችን እየፈለጉ ነው። ማን መሳተፍ እንደሚችል እና የጥናት ቡድኑን እንዴት መገናኘት እንደሚቻል ለማየት ጥናቱን ክፈቱ።
Official study text (English)
ለጥናት ተሳታፊዎችን እየፈለጉ ነው? በዚህ ገጽ ላይ በ$99 ለ30 ቀናት ያስቀምጡት →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
ተሳታዮችን በመፈለግ ላይደረጃ 3
- Advocate Good Shepherd Hospital, Barrington · 9 ማይል ርቀት
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
ተሳታዮችን በመፈለግ ላይደረጃ 3
- Illinois Cancer Specialists, Arlington Heights
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
ተሳታዮችን በመፈለግ ላይደረጃ 3
- Illinois Cancer Specialists, Arlington Heights
Prospective External Control Cohort In Patients With Newly Diagnosed Advanced or Metastatic EGFR Mutant Non-Small Cell Lung Cancer
ተሳታዮችን በመፈለግ ላይየመመልከት ጥናት
- Northwest Oncology & Hematology, Elk Grove Village · 6 ማይል ርቀት
An External Control Arm Study in Non-Small Cell Lung Cancer
ተሳታዮችን በመፈለግ ላይየመመልከት ጥናት
- Northwest Oncology and Hematology, Rolling Meadows · 2 ማይል ርቀት
- Northwest Oncology and Hematology, Elk Grove · 6 ማይል ርቀት
- Northwest Oncology and Hematology, Hoffman Estates · 6 ማይል ርቀት
- እና 1 ተጨማሪ
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
ተሳታዮችን በመፈለግ ላይደረጃ 2/3
- Local Institution - 007-883-A, Arlington Heights
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
ተሳታዮችን በመፈለግ ላይደረጃ 3
- Illinois Cancer Specialists, Arlington Heights
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
ተሳታዮችን በመፈለግ ላይደረጃ 3
- Northwest Oncology & Hematology, Barrington · 9 ማይል ርቀት
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
ተሳታዮችን በመፈለግ ላይደረጃ 2
- Advocate Good Shepherd Hospital, Barrington · 9 ማይል ርቀት
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
ተሳታዮችን በመፈለግ ላይደረጃ 2
- Advocate Good Shepherd Hospital, Barrington · 9 ማይል ርቀት
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
ተሳታዮችን በመፈለግ ላይደረጃ 2/3
- Advocate Good Shepherd Hospital, Barrington · 9 ማይል ርቀት
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
ተሳታዮችን በመፈለግ ላይየመመልከት ጥናት
- Advocate Good Shepherd Hospital, Barrington · 9 ማይል ርቀት
በሌሎች ከተሞች ለኖን-ስማል ሴል የሳንባ ካንሰር የሚደረጉ ጥናቶች
- Houston, TX145 ጥናቶች
- New York City, NY121 ጥናቶች
- Arlington, VA104 ጥናቶች
- Nashville, TN97 ጥናቶች
- Boston, MA90 ጥናቶች
- Los Angeles, CA87 ጥናቶች
- St. Louis, MO73 ጥናቶች
- Chicago, IL61 ጥናቶች
- Baltimore, MD60 ጥናቶች
- San Antonio, TX59 ጥናቶች
- Columbus, OH57 ጥናቶች
- Washington, DC55 ጥናቶች
በArlington Heights ውስጥ ያሉ ሌሎች ጥናቶች
- የኮሎሬክታል ካንሰር12 ጥናቶች
- የሳንባ ካንሰር9 ጥናቶች
- የጡንቻ ካንሰር7 ጥናቶች
- የልብ ድካም7 ጥናቶች
- Metastatic Cancer6 ጥናቶች
- አልሰራቲቭ ኮላይቲስ6 ጥናቶች
- የኮሎን ካንሰር6 ጥናቶች
- የእንቁላል ካንሰር5 ጥናቶች
- ከባድ ሰውነት5 ጥናቶች
- ከመጠን በላይ ክብደት5 ጥናቶች
- የፕሮስቴት ካንሰር3 ጥናቶች
- የቆዳ ችግሮች3 ጥናቶች
ከ ClinicalTrials.gov የተገኘ መረጃ፣ በ6 ኦክቶ 2026 የተሰብሰቡ። እያንዳንዱ ጥናት የራሱን ቅድመ ሁኔታ ይወስናል፤ የጥናት ቡድኑ ማን መሳተፍ እንደሚችል ይወስናል።